Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cunney, R.
Right arrow Articles by Walshe, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cunney, R.
Right arrow Articles by Walshe, J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrology Dialysis Transplantation, Vol 13, Issue 11 2842-2846, Copyright © 1998 by Oxford University Press


ORIGINAL ARTICLES

Clostridium difficile colitis associated with chronic renal failure

R Cunney, C Magee, E McNamara, E Smyth and J Walshe
Departments of Clinical Microbiology and Nephrology, Beaumont Hospital, Dublin, Ireland; Corresponding author at: Services of Infectious Diseases, Hamilton Health Sciences corporation, McMaster University Medical Center, Room 2N33, 1200 Main Street West, Hamilton ON L8N 3Z5, Canada

Background: Clostridium difficile-associated diarrhoea (CDAD) is a potentially life-threatening illness which has been shown to be more common and more severe in patients with chronic renal failure (CRF) than in other groups. A review of CDAD in our nephrology unit was carried out. Methods: A review of microbiology and histology records identified 32 cases of CDAD in the nephrology unit over a 14-month period. Patient notes were reviewed to identify risk factors, clinical features and outcome. Available isolates of C. difficile underwent 16S ribosomal RNA typing. Results: The incidence of CDAD in the nephrology unit was 10.7 per 1000 admissions, compared to 2.7 per 1000 in other areas of the hospital (P<0.0001). CDAD was considered the sole or principal cause of death in six (19%) and was considered a contributing factor in a further seven (22%). Mortality was significantly higher among patients with established CRF (P=0.04). Seven cases occurred as a cluster, over a 1-month period. Isolates from this cluster, along with comparative strains from other areas of the hospital, were found to be PCR type 1. Diarrhoea occurred in 28 (89%) of cases, pyrexia in 17 (53%) and ileus or abdominal pain in 14 (44%). Six patients responded to discontinuation of antibiotics alone and 22 required metronidazole and/or vancomycin. Three patients had colectomy and one caecostomy because of toxic megacolon. Four patients died before specific therapy could be given and in two of these cases the diagnosis was made at autopsy. Twenty-six patients had a record of recent antibiotic therapy. Of these, 15 had at least one agent considered to be inappropriate (excessively broad spectrum agent in 11, excessive duration of therapy in four). Nine patients had only received antibiotics prior to admission. Conclusions: CDAD carries a high mortality in nephrology patients especially those with established CRF. The diagnosis may be missed if a careful antibiotic history is not taken, including agents received prior to admission. Rational antibiotic prescribing and adherence to infection control measures are vital to reduce the incidence of this serious condition. Key words: antibiotics; chronic renal failure; Clostridium difficile; colitis; uraemia
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Infect. Immun.Home page
X. He, X. Sun, J. Wang, X. Wang, Q. Zhang, S. Tzipori, and H. Feng
Antibody-Enhanced, Fc Gamma Receptor-Mediated Endocytosis of Clostridium difficile Toxin A
Infect. Immun., June 1, 2009; 77(6): 2294 - 2303.
[Abstract] [Full Text] [PDF]


Home page
NDT PlusHome page
T Chandrasekar, N Naqvi, A Waddington, R. Cooke, H. Anijeet, C. Gradden, K. Abraham, and C. Wong
Intravenous immunoglobulin therapy for refractory Clostridium difficile toxin colitis in chronic kidney disease: case reports and literature review
NDT Plus, February 1, 2008; 1(1): 20 - 22.
[Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
E. E. Hamm, D. E. Voth, and J. D. Ballard
Identification of Clostridium difficile toxin B cardiotoxicity using a zebrafish embryo model of intoxication
PNAS, September 19, 2006; 103(38): 14176 - 14181.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
S. Dial, J. A. C. Delaney, A. N. Barkun, and S. Suissa
Use of Gastric Acid-Suppressive Agents and the Risk of Community-Acquired Clostridium difficile-Associated Disease
JAMA, December 21, 2005; 294(23): 2989 - 2995.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
M. A. Little, A. O'Riordan, B. Lucey, M. Farrell, M. Lee, P. J. Conlon, and J. J. Walshe
A prospective study of complications associated with cuffed, tunnelled haemodialysis catheters
Nephrol. Dial. Transplant., November 1, 2001; 16(11): 2194 - 2200.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
J. Popoola, A. Swann, and G. Warwick
Clostridium difficile in patients with renal failure -- management of an outbreak using biotherapy
Nephrol. Dial. Transplant., May 1, 2000; 15(5): 571 - 574.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
T. Kovithavongs, R. J. Cunney, C. Magee, E. McNamara, E. G. Smyth, and J. Walshe
Clostridium difficile colitis associated with chronic renal failure
Nephrol. Dial. Transplant., September 1, 1999; 14(9): 2256 - 2257.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.